The COVID-19 pandemic continued to dominate much of the health news in 2021. That's not surprising, given the more than 800,000 COVID-19 deaths and counting in the United States alone.
Some in the cancer research community, in fact, turned their attention to the pandemic's impact on people with cancer, studying topics ranging from the efficacy of COVID vaccines for people who have been treated for cancer to how the pandemic has affected cancer care. Indeed, some of the most popular Cancer Currents stories published this past year were related to COVID-19.
But readers wanted to know about more than just the pandemic. And there was plenty of exciting cancer research to report on. So, in case you missed any of these stories the first time around, here are our most-read stories of 2021, as well as some other noteworthy stories from this past year.
Finally, we'd like to thank you for your continued support of Cancer Currents. If you find our reporting important or helpful, please share it with friends and colleagues and encourage them to subscribe.
Dr. Steven Pergam of the Fred Hutchinson Cancer Research Center discusses the importance of COVID-19 vaccination for people being treated for cancer and cancer survivors. This post was updated on April 9, 2021, with additional questions and answers.
FDA has approved the first KRAS-blocking drug, sotorasib (Lumakras). The approval, which covers the use of sotorasib to treat some patients with advanced lung cancer, sets the stage for other KRAS inhibitors already in development, researchers said.
Cancer cells that are left over after treatment can go into a "dormant" state for years. A new study in mice suggests that stress hormones may trigger a chain reaction that wakes up dormant cancer cells, causing tumors to form again.
People with blood cancers seem to be less protected by COVID-19 vaccines than those with other cancers and people without cancer, three new studies suggest. Experts believe this limited effectiveness is likely due to patients' weakened immune systems.
The Food and Drug Administration has approved idecabtagene vicleucel (Abecma) for some people with multiple myeloma. The approval is based, in part, on a small study in which ide-cel partially or completely shrank tumors in 72% of patients.
Misinformation about cancer is abundant on social media, including stories that describe miraculous results from treatments that are unproven and potentially harmful. Researchers are studying misinformation and its impact on people with cancer.
More than a decade after vaccination, women who had received a single dose of the HPV vaccine continued to be protected against infection with the two cancer-causing HPV types targeted by the vaccine, an NCI-funded clinical trial shows.
Can some people with HPV-related oropharyngeal cancer, a type of head and neck cancer, get less intense treatment without risking their cancer coming back? Researchers are trying to find out.
Women are far more likely than men to be diagnosed with small thyroid cancers that probably would have never caused problems during their lifetime, a new study finds. The results may help explain why thyroid cancer seems to be more common in women.
Researchers have developed synthetic antibodies, called diabodies, that block the activity of two of the most notorious cancer-related proteins, RAS and p53. In experiments in mice, the synthetic antibodies shrank tumors with these mutated proteins.
This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892
No comments:
Post a Comment